Cabaletta Bio Stock Forward View - Triple Exponential Smoothing
| CABA Stock | USD 3.20 0.14 4.58% |
The successful prediction of Cabaletta Bio's future price could yield a significant profit. Please note that this module is not intended to be used solely to calculate an intrinsic value of Cabaletta Bio and does not consider all of the tangible or intangible factors available from.
Currently, RSI for Cabaletta Bio stands at 55, indicating neutral momentum. A midpoint RSI reading suggests neither buyers nor sellers hold a decisive advantage at this juncture.Momentum
Impartial
Oversold | Overbought |
This view frames how Cabaletta Bio responds to recent headlines and peer activity within its market context.
The Triple Exponential Smoothing forecasted value of Cabaletta Bio on the next trading day is expected to be 3.20 with a mean absolute deviation of 0.12 and the sum of the absolute errors of 7.25.Cabaletta Bio after-hype prediction price | $ 3.2 |
The hype panel supports comparisons with forecasting models, technical signals, analyst consensus, and earnings.
Cabaletta | Build portfolio with Cabaletta Stock |
Cabaletta Bio Additional Predictive Modules
Predictive models for Cabaletta Bio combine technical indicators with statistical methods to estimate probable price trajectories. Predictive accuracy varies by market regime - trending markets and range-bound markets favor different model types.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Triple Exponential Smoothing Price Forecast For the 17th of March 2026
Given 90 days horizon, the Triple Exponential Smoothing forecasted value of Cabaletta Bio on the next trading day is expected to be 3.20 with a mean absolute deviation of 0.12 , mean absolute percentage error of 0.03 , and the sum of the absolute errors of 7.25 .Please note that although there have been many attempts to predict Cabaletta Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Cabaletta Bio's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Cabaletta Bio | Cabaletta Bio Price Prediction | Research Analysis |
Forecasted Value
The next-day forecast for Cabaletta Bio focuses on identifying predictive downside and upside bands that can frame a realistic trading range. The current forecast range spans downside near 0.03 and upside near 9.02.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Triple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Cabaletta Bio stock data series using in forecasting. Note that when a statistical model is used to represent Cabaletta Bio stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | -0.0228 |
| MAD | Mean absolute deviation | 0.1228 |
| MAPE | Mean absolute percentage error | 0.0452 |
| SAE | Sum of the absolute errors | 7.2453 |
Mean reversion is the tendency of Cabaletta Bio's price to return to its historical average after periods of extreme deviation. Investors who identify when Cabaletta Bio's is significantly above or below its mean may find compelling entry or exit opportunities.
After-Hype Price Density Analysis
This probability density chart for Cabaletta Bio shows how predicted future prices are distributed across a range of outcomes. Wider distributions reflect higher uncertainty, while narrow distributions indicate greater consensus about Cabaletta Bio's likely price range.
Next price density |
| Expected price to next headline |
Estimiated After-Hype Price Volatility
Historical news analysis for Cabaletta Bio provides statistically derived price boundaries for the session following a significant headline. Cabaletta Bio's after-hype downside and upside margins for the prediction period are 0.16 and 9.01, respectively. These boundaries are derived from Cabaletta Bio's past price reactions to comparable news events, not forward-looking forecasts.
Current Value
The next after-hype price estimate for Cabaletta Bio is modeled on a 3 months horizon and is intended to show how price could normalize after sentiment pressure fades. Used correctly, the estimate adds context around potential normalization rather than promising a specific realized outcome.
Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Cabaletta Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cabaletta Bio backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Cabaletta Bio, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.64 | 5.81 | 0.00 | 0.00 | 0 Events | 0 Events | In 5 to 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
3.20 | 3.20 | 0.00 |
|
Hype Timeline
Cabaletta Bio is currently traded for 3.20. The company stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Cabaletta is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is currently at 0.64%. %. The volatility of related hype on Cabaletta Bio is about 0.0%, with the expected price after the next announcement by competition of 3.20. About 79.0% of the company shares are held by institutions such as insurance companies. The book value of Cabaletta Bio was currently reported as 1.45. The company recorded a loss per share of 2.4. Cabaletta Bio had not issued any dividends in recent years. Given the investment horizon of 90 days the next forecasted press release will be in 5 to 10 days. Use Historical Fundamental Analysis of Cabaletta Bio to cross-verify projections for Cabaletta Bio. The view supplies historical context for the projection discussion.For more detail on how to invest in Cabaletta Stock please use our How to Invest in Cabaletta Bio guide.Related Hype Analysis
Monitoring how Cabaletta Bio's competitors respond to market-moving news provides a leading indicator for how Cabaletta Bio itself may react to similar events. Peer hype analysis captures this cross-asset sentiment signal.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| EDIT | Editas Medicine | 0.00 | 0 per month | 4.73 | 0.03 | 11.64 | -6.01 | 26.62 | |
| ALLO | Allogene Therapeutics | 0.00 | 0 per month | 4.64 | 0.15 | 11.11 | -7.79 | 28.70 | |
| CAPR | Capricor Therapeutics | 0.00 | 0 per month | 3.90 | 0.08 | 9.04 | -6.69 | 22.92 | |
| KYTX | Kyverna Therapeutics Common | 0.00 | 0 per month | 7.79 | 0.01 | 9.88 | -8.52 | 32.52 | |
| LYEL | Lyell Immunopharma | 0.00 | 0 per month | 0.00 | -0.11 | 6.12 | -9.09 | 27.78 | |
| AVIR | Atea Pharmaceuticals | 0.00 | 0 per month | 1.52 | 0.31 | 8.20 | -2.91 | 17.79 | |
| PRQR | ProQR Therapeutics BV | 0.00 | 0 per month | 0.00 | -0.07 | 5.33 | -5.73 | 20.95 | |
| IMMP | Immutep Ltd ADR | 0.00 | 0 per month | 0.00 | -0.11 | 6.02 | -4.64 | 90.43 | |
| LXEO | Lexeo Therapeutics Common | 0.00 | 0 per month | 0.00 | -0.10 | 6.22 | -6.37 | 34.26 | |
| HUMA | Humacyte | 0.00 | 0 per month | 4.60 | 0.03 | 11.11 | -7.29 | 43.72 |
Other Forecasting Options for Cabaletta Bio
For investors of all experience levels considering Cabaletta, understanding Cabaletta Bio's price movement is fundamental to making sound investment decisions. Cabaletta Stock price charts contain significant noise that can obscure meaningful trends.Cabaletta Bio Related Equities
The following equities are related to Cabaletta Bio within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Cabaletta Bio against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Cabaletta Bio Market Strength Events
Market strength indicators for Cabaletta Bio stock provide investors with a framework for assessing how the security responds to changing market conditions. These indicators help determine optimal entry and exit points for trading Cabaletta Bio.
Cabaletta Bio Risk Indicators
Assessing Cabaletta Bio's risk indicators is a critical component of any rigorous approach to forecasting its future price. Understanding the risk involved in holding Cabaletta Bio's allows investors to make an informed decision about whether to accept or mitigate that exposure.
| Mean Deviation | 4.26 | |||
| Semi Deviation | 3.91 | |||
| Standard Deviation | 5.81 | |||
| Variance | 33.79 | |||
| Downside Variance | 19.13 | |||
| Semi Variance | 15.29 | |||
| Expected Short fall | -5.62 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Cabaletta Bio
Coverage intensity for Cabaletta Bio matters because narrative visibility can influence sentiment, participation, and volatility around the name. This is most useful when investors want to understand why a security is suddenly drawing more public discussion.
Contributor Headline
Latest Perspective From Macroaxis
Cabaletta Bio Short Properties
Short sentiment tied to Cabaletta Bio matters because heavier bearish pressure can change how quickly future price expectations become unstable. The practical goal is to identify when the balance between long and short participation may be changing the quality of the setup.
| Common Stock Shares Outstanding | 49.5 M | |
| Cash And Short Term Investments | 164 M |
More Resources for Cabaletta Stock Analysis
Understanding Cabaletta Bio typically begins with financial statements and long-term trend review. Cabaletta Bio's financial ratios translate raw accounting data into comparable profitability and efficiency signals. Selected reports below provide context for Cabaletta Stock:Use Historical Fundamental Analysis of Cabaletta Bio to cross-verify projections for Cabaletta Bio. The view supplies historical context for the projection discussion.For more detail on how to invest in Cabaletta Stock please use our How to Invest in Cabaletta Bio guide.Cabaletta Bio currently shows ROE of -101.06%, market cap of 294.57 Million. Investors get more value from Cabaletta Bio analysis when it is combined with the construction and diversification tools listed below. Within the Healthcare space, Cabaletta Bio peer comparison and risk tools below help frame relative strengths and weaknesses. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Investors evaluate Cabaletta Bio using market value and book value, each describing different facets of the business. Cabaletta Bio's market capitalization is 294.57 M. At P/B 2.11, Cabaletta Bio trades moderately above book value. Enterprise value stands at 160.42 M. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
Note that Cabaletta Bio's intrinsic value and market price are different measures derived from different inputs. For Cabaletta Bio, key inputs include a P/B ratio of 2.11, and ROE of -101.06%. In practice, Cabaletta Bio price is set by the continuous auction process on its listing exchange.